Gary Charles Robb sold $556k of CORT
Chief Business Officer at CORCEPT THERAPEUTICS INC. 11,000 shares at an average of $50.50, traded Jan 2, 2025, filed Jan 6, 2025.
Score components
- +15RoleOfficer
- +19Trade size$556k at market
- +10Share of holdings soldSold 35% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-002439, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2025 | MOption exercise Common Stock10b5-1 | +11,000 | $3.29 | $36k | 31,119 | Jan 6, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock10b5-1 | -11,000 | $50.50 | $556k | 20,119 | Jan 6, 2025 |
| Jan 3, 2025 | MOption exercise Common Stock10b5-1 | +3,037 | $3.29 | $9,992 | 23,156 | Jan 6, 2025 |
| Jan 2, 2025 | MOption exercise Stock option (right to buy)derivative10b5-1 | -11,000 | $0.00 | $0 | 3,037 | Jan 6, 2025 |
| Jan 3, 2025 | MOption exercise Stock option (right to buy)derivative10b5-1 | -3,037 | $0.00 | $0 | 0 | Jan 6, 2025 |
Related signals
Other insiders at CORCEPT THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | CORCEPT THERAPEUTICS INC | Sean Maduck See Remarks | $2.9M 25,000 shares | -242% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Joseph Douglas Lyon See Remarks | $1.2M 10,000 shares | -154% | |
| 45Moderate | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $967k 8,333 shares | -68% | |
| 20Weak | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $30k 296 shares | -7% | |
| 35Weak | CORCEPT THERAPEUTICS INC | James N Wilson director | $1.1M 10,000 shares | -1% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Joseph Douglas Lyon See Remarks | $1.1M 10,000 shares | -64% | |
| 45Moderate | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $6.5M 58,333 shares | -93% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Sean Maduck See Remarks | $2.9M 25,000 shares | -72% | |
| 30Weak | CORCEPT THERAPEUTICS INC | Joseph K Belanoff Chief Executive Officer | $3.2M 40,000 shares | -1% | |
| 30Weak | CORCEPT THERAPEUTICS INC | Joseph K Belanoff Chief Executive Officer | $3.0M 40,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.